Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Piper Sandler

Analysts at Piper Sandler began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set an “overweight” rating and a $48.00 price target on the stock.

Other equities research analysts have also recently issued reports about the company. Wedbush started coverage on Avalo Therapeutics in a research note on Friday, February 21st. They set an “outperform” rating and a $18.00 target price on the stock. BTIG Research assumed coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 target price for the company. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Buy” and an average price target of $35.33.

Avalo Therapeutics Stock Up 10.8 %

AVTX opened at $7.31 on Friday. The firm’s fifty day moving average price is $7.60 and its two-hundred day moving average price is $9.27. Avalo Therapeutics has a 1 year low of $4.28 and a 1 year high of $34.46.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors have recently modified their holdings of AVTX. Tower Research Capital LLC TRC increased its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares during the last quarter. Marshall Wace LLP purchased a new position in Avalo Therapeutics during the fourth quarter worth about $114,000. Walleye Capital LLC acquired a new position in Avalo Therapeutics during the fourth quarter valued at $145,000. Northern Trust Corp acquired a new position in Avalo Therapeutics in the 4th quarter worth about $168,000. Finally, Bank of Montreal Can bought a new position in shares of Avalo Therapeutics during the fourth quarter worth about $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.